P rimary pulmonary hypertension (PPH) is a rare disease associated with a poor prognosis. 1 It is usually diagnosed only after pulmonary artery pressure (PAP) is markedly elevated. 2 The disease is thought to develop from reversible vasoconstrictive to irreversible proliferative stages. Although therapy with prostacyclin has improved the symptoms, pulmonary hemodynamics, and prognosis, 3, 4 treatment of the early stages may be easier, more effective, and less costly if vasoconstriction is predominant, because it may be effectively treated with calcium channel blockers. 5 Therefore, it might be of great value to identify latent PPH to start therapy at an early stage. Unfortunately, at present, there are no known clinical signs or markers of the early stages of PPH. Insights derived from the familial form of PPH might be helpful in this regard because the clinical or pathological features are not different from the sporadic form. 6 Because familial PPH appears to be a monogenetic disease with an autosomal-dominant inheritance, 7 one would expect half of the siblings of PPH patients to be affected. However, analysis of 24 families has shown an incomplete age-and sex-related penetrance of the disease, suggesting that some family members are asymptomatic gene carriers. 7 Linkage to chromosome 2q31-32 has been reported in 7 families. 8, 9 The causal gene and identification of family members at risk has not emerged to date. We hypothesized that the clinically asymptomatic gene carriers in PPH families could be identified by a systematic noninvasive assessment of PAP at rest and during exercise.
Therefore, stress Doppler echocardiography (SE) and linkage analysis on members of 2 German PPH families (designated families A and B) were performed.
Methods

Study Population and Design
All 79 living members of 2 families with PPH were invited to participate in a clinical and genetic evaluation. Only 2 declined to be studied. From 67 members, blood samples were taken for genetic analysis. Of these, 52 were assessed clinically. They were nativeborn residents of a low-altitude area and were studied in Heidelberg, Germany, at an altitude of 100 m. The study was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg, and the members gave informed written consent before the study. 
Clinical Procedures
Stress Doppler Echocardiography
The participants were examined on a supine bicycle ergometer (model 8420, KHL Corp) as described previously. 12, 13 After videotape review of echocardiographic images and Doppler signals, measurements were made again with an offline system (Echocom) in random order and in a blinded fashion. PASP was estimated from peak tricuspid regurgitation jet velocities according to the following equation: PASPϭ4(V) 2 ϩ5 mm Hg, where V is the peak velocity (in m/s) of tricuspid valve regurgitant jet, and 5 mm Hg is the estimated right atrial pressure. 14 Maximal tricuspid velocity was measured at the highest coherent boundary on the spectral wave form. Signals were considered technically adequate if they had complete envelopes with well-defined borders. In subjects with inadequate Doppler signals, SE was repeated within 6 to 18 months. PASP values Ͻ25 mm Hg at rest and Յ40 mm Hg during exercise were classified as normal. 6, 15, 16 The right ventricular (RV) and atrial areas were obtained in apical 4-chamber views by using planimetry as described by Bommer et al. 17 Left ventricular (LV) volumes and ejection fractions were calculated by the disk summation method (modified Simpson's rule). Cardiac output was estimated from LV volumes in the cardiac cycle.
Right Heart Catheterization
Right heart catheterization was carried out simultaneously with SE in all 4 PPH patients and in 12 family members with the use of a Swan-Ganz balloon-tipped catheter (Baxter) placed in the pulmonary artery. Pressures at rest and during supine bicycle exercise were recorded with a polygraph (Hellige). Cardiac output and mixed venous oxygen saturation were not obtained for all members at rest and during exercise.
Safety
All examinations were performed by 3 physicians: one performed the echocardiographic examinations, the second performed the right heart catheterization, and the third monitored the ECG, heart rates, blood pressures, and oxygen saturation at rest and during exercise.
Linkage Analysis
Genomic DNA was extracted from whole blood by use of standard salt precipitation protocols. Genotypes for chromosome 2-specific microsatellite markers CHRNA1, D2S364, D2S2336, and D2S369 were obtained by polymerase chain reaction, followed by polyacrylamide gel electrophoresis on an ALF express sequencer. For linkage analysis, we studied the data with the use of 2 alternative statistical models. First, we considered only the PPH patients as affected. Second, we considered the PPH patients and all members with abnormal PASP response as affected. Multipoint logarithm of the odds (LOD) scores were calculated by using the program LINK-AGE. 18 LOD score calculations were performed with an age-and sex-dependent disease penetrance increasing from 10% within 10 years to 70% at age Ͼ60 years in men, according to Morse et al. 8 The estimated PPH gene frequencies corresponded to a disease prevalence of 1/100 000.
Statistical Methods
Data are given as meanϮSD values. All measurements of PAP were calculated as the means of 3 cardiac cycles. Comparisons between groups were assessed by the Mann-Whitney-Wilcoxon test. Linear regression analysis was used to correlate invasive and noninvasive PASP measurements. A probability value of PϽ0.05 was considered significant.
Results
Clinical Data
Study Population
Of 52 family members examined, 3 (mean age 58Ϯ13 years) were excluded from further clinical analysis because of elevated mean pulmonary artery wedge pressure (31Ϯ3 mm Hg) during exercise secondary to systemic hypertension (maximal systemic arterial systolic pressure 210Ϯ10 mm Hg). One member (A:III-18, from family A, shown in Figure 1a ) had undergone surgery for an aortic isthmus stenosis in 1968. Four others were excluded because of inadequate Doppler signals during exercise. These 7 family members were assigned to an undefined status (Figure 1 ).
PPH Patients
Manifest PPH had been diagnosed previously in 4 living patients, aged 28 to 43 years, with a mean PASP of 73Ϯ16 mm Hg at rest. In family B, 2 sisters (B:III-2 and B:III-3), aged 28 and 19 years, with an end-stage disease had undergone double-lung transplantation.
Normal PASP Response to Exercise (NR Group)
In 27 members (normal response [NR] group), the PASP was within normal limits at rest (24Ϯ4 mm Hg) and during exercise (37Ϯ3 mm Hg, ⌬PASP 12Ϯ2 mm Hg, Figure 2) . The physical examination revealed that none of them had cardiopulmonary symptoms or abnormalities. Two had nonspecific ECG changes at rest unchanged during exercise. The results of chest x-ray, pulmonary function test, echocardiogram, and SE were all within normal limits. Right heart catheterization in 2 unaffected members revealed normal PAPs.
Abnormal PASP Response to Exercise (AR Group)
Fourteen members with normal PASP at rest revealed a pathological increase of PASP (Ͼ40 mm Hg) during supine bicycle exercise and were classified as the abnormal response (AR) group (Figures 1 and 2) . Two of them revealed exertional dyspnea (New York Heart Association class II),
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and one suffered from exertional dizziness. The remaining AR members were asymptomatic. At rest, all examined members were in sinus rhythm. During exercise, one AR member revealed competing atrial foci, and one developed supraventricular tachycardia.
Exercise Capacity
The AR and NR groups were similar in body weight, height, and exercise parameters ( Table 1 ). The exercise capacity was similar in the AR and NR groups (107Ϯ36 and 119Ϯ41 W, respectively) and was within the normal range, considering the supine exercise position and the fact that 3 AR and 14 NR members were children aged 6 to 16 years. The mean age of the NR group (21Ϯ13 years) was lower than that of the AR group (36.9Ϯ20 years, Pϭ0.02). However, if the comparison of the AR and the NR groups was restricted to members Ͻ40 years of age, the PASP differences were still significant, indicating that they were not age-related. At rest, both groups had similar cardiac outputs, heart rates, and systemic blood pressures (Table 1) . During exercise, the mean PASP increased to significantly higher levels in AR subjects (from 23Ϯ4 to 56Ϯ11 mm Hg, ⌬PASP 32Ϯ11 mm Hg) than in NR subjects (from 24Ϯ4 to 37Ϯ3, ⌬PASP 13Ϯ4 mm Hg; PϽ0.0001; Figure 2 ). Right heart catheterization was performed in all 4 PPH patients, in 3 members with secondary pulmonary hypertension, and in 2 NR and 7 AR members ( 0001 , and SEE 7.0 mm Hg). In 27 of the NR and AR members, Doppler signals became inadequate at maximal workloads corresponding to a heart rate Ͼ135 bpm. Despite these technical limitations, both groups could be discriminated according to their PASP response at submaximal levels of exercise (50 to 125 W).
LV and RV Function at Rest and During Exercise
The 4 patients with PPH revealed dilated and impaired RV. All other examined family members had normal RV and right atrial diameters and normal RV and LV function at rest and during exercise. LV ejection fraction did not correlate with PASP at rest or during exercise. RV end-diastolic and A:III-18  45  100  28  55  12  47  7  31  9  37  16  140  200   A:III-20  58  100  26  65  24  44  10  18  15  27  35  140  220   B:II-2  63  75  21  67  20  46  12  20  15  29  30  145  210   Mean  55  92  25  62  19  46  10  23  13  31  27  142  210 Workload indicates maximal supine bicycle exercise; PADP, pulmonary artery diastolic pressure; PAMP, pulmonary artery mean pressure; PCWP, pulmonary capillary wedge pressure; SASP, systemic arterial systolic pressure; SADP, systemic arterial diastolic pressure; SAMP, systemic arterial mean pressure; RAP, right atrial pressure; SaO 2 , systemic arterial oxygen saturation; and PH, pulmonary hypertension.
end-systolic areas were normal in all AR and NR subjects and did not change significantly during exercise (Table 3) .
Genetic Studies
Pedigree analysis indicated an autosomal-dominant mode of inheritance with incomplete penetrance in both families. Positive LOD scores for linkage between manifest PPH and chromosome 2q31-32 markers were found in families A and B (LOD score 0.83 at D2S364). Although not significant in itself, this score indicated cosegregation of PPH with the disease locus mapped by Morse et al 8 and Nichols et al 9 and adds to the evidence for linkage. A disease haplotype was identified in all 4 PPH-patients, in all 14 AR members, in 2 NR subjects, and in 2 members with unknown disease status due to inadequate Doppler signals (Figure 1) . If the AR members were considered to be affected, the multipoint LOD score increased to 4.4 at a locus 2.5 cM proximal to D2S364 and 1.5 cM distal to CHRNA1. If PASP of 40 mm Hg was used as a cutoff level, the sensitivity of SE for identifying the carriers of the disease-associated haplotype was 82.4% (95% CI 68.3 to 98.8). The 2 carriers (A:IV-14 and A:IV-25 [in family A]) that showed a normal PASP response to exercise were 11 and 17 years old, respectively. In family A, PASP increased from 21 to 37 mm Hg in one member (A: and from 19 to 38 mm Hg in another (A:IV-25). Because we could not attribute their unaffected disease status to recombination events, a reduced penetrance of the AR trait at young ages appears to be the best explanation for the incomplete sensitivity of carrier identification by SE. Within this study population, SE had a 100% specificity (95% CI 87.2 to 100) and 87.5% sensitivity in identifying asymptomatic carriers with the PPH gene.
Discussion
The present study is the first report on a systematic clinical assessment of PAPs at rest and during exercise in members of families with PPH. Our results indicate that asymptomatic gene carriers can be identified clinically by their pathological pulmonary artery response to exercise with high specificity and sensitivity.
Although there are few studies involving the normal limits of PAP in healthy individuals, previous invasive 15, 16, 19 and noninvasive 12, 20 studies have shown that at sea level in normoxia, PASP does not exceed 40 mm Hg in normal subjects even during heavy exercise, with the exception of some extremely well-trained individuals during a workload of 300 W and an increase of cardiac output of Ͼ25 to 30 L/min. 21, 22 In 14 members of the 2 families, a pathological rise of PASP during normoxic supine bicycle exercise was documented by continuous-wave Doppler at a workload of 50 to 150 W. In all 14 AR members, secondary causes of pulmonary hypertension could be excluded. The values obtained by continuous-wave Doppler correlated closely with the PAPs measured invasively. Although all 14 members were carriers of the disease haplotype, only 3 had nonspecific symptoms. The factors that may trigger symptomatic pulmonary hypertension in asymptomatic carriers are unknown. Only further follow-up studies can clarify at what stage of the disease these findings occur and whether the findings represent susceptibility or an early stage of PPH. These studies may also evaluate the factors underlying manifestation of the disease. Whether early diagnosis will allow an increased number of patients to be effectively treated with simpler therapeutic interventions, such as chronic oral calcium channel blockade 5 as opposed to continuous prostanoid therapy, 3, 4 remains unknown. SE may allow the noninvasive investigation of such a question.
Our molecular genetic analysis provides evidence that manifest PPH and abnormal PASP response to exercise are inherited as a dominant trait, localized on chromosome 2q31-32. The lack of evidence for genetic heterogeneity in the linkage analyses reported so far suggests that a single major gene may account for all cases of familial PPH. The gene defect was nonpenetrant with respect to the AR trait in 2 members (A:IV-14 and A:IV-25), aged 11 and 17 years. This was expected in light of the previously documented low penetrance for PPH at young ages. 8, 23 In contrast, Loyd et al 7 have reported genetic anticipation, with this disease being more manifest at younger ages. Therefore, these carriers might have been missed clinically with the use of noninvasive estimation of PASP. On the other hand, all AR members shared the disease haplotype with the 4 PPH patients. Therefore, the pathological PASP response to exercise in the members of PPH families may be one of the first clinical manifestations of PPH and may indicate carriers of the PPH gene. Relaying this information to family members is a very delicate issue. Family assessment and genetic counseling should be performed only in conjunction with an experienced counselor as well as with the pulmonary hypertension medical team and other family members involved. The risks of exercise testing in family members of PPH patients, despite being very low, necessitate that during performance of the exercise test, all members will be carefully monitored by an experienced team including either 2 physicians or 1 physician and a nurse.
Identification of susceptibility to PPH by estimation of a pathological pulmonary artery response to exercise and by molecular genetic analysis opens new insights into the natural course of the disease and may lead to an earlier treatment. It may also improve the possibility of linkage analysis, even in small families. Further molecular genetic analysis of additional families may help to narrow the identified genetic region on chromosome 2q31-32. SE during supine bicycle exercise may be a useful screening method to identify members with pathological PASP response in families with PPH. Therefore, SE should be offered at least to all firstdegree family members of PPH patients even if they reveal normal resting PASP.
